TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30672254
Drug: Fan-needle radiofrequency
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fan-needle radiofrequency guided by meridians-muscles theory, treated at tendon nodes around knee joints (ashi points), 4 points per treatment, once every two weeks for 2 treatments.
Study: 30672254
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of celecoxib capsules, 1 capsule every day for 4 weeks.
Study: 14597936
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg/d
Study: 17035949
Drug: Spironolactone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25 mg/day for 1 year)
Study: 17035949
Drug: Angiotensin‐converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin‐converting enzyme inhibitors and/or angiotensin type 1 receptor antagonists alone
Study: 24661576
Drug: Xylo-oligosaccharides (XOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylo-oligosaccharides (XOS) 8 g/d
Study: 12370798
Drug: Intranasal calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal calcitonin 200 IU daily for 3 months
Study: 10213650
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (midodrine 10 mg and dialysate temperature 35.5 degrees C)
Study: 6111161
Drug: Nitroglycerin (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (0.8 mg p. o.)
Study: 6111161
Drug: Beta-receptor-blocker (Mepindolol)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-receptor-blocker (Mepindolol)
Study: 25994567
Drug: corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: corn oil therapy (control)
Study: 20191935
Drug: Gaboxadol 15
Normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaboxadol 15 mg
Study: 25195191
Drug: Tiagabine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine 15 mg
Study: 23234802
Drug: Inhaled mannitol
Normalized name: mannitol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled mannitol (400 mg)
Study: 21241954
Drug: CLON‐XR 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLON‐XR 0.4 mg/day
Study: 15097154
Drug: TPV/r 300/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPV/r 300/200 mg twice daily
Study: 15097154
Drug: TPV/r 1200/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPV/r 1200/200 mg twice daily
Study: 15097154
Drug: TPV 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPV 1200 mg
Study: 15097154
Drug: TPV/r 300/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPV/r 300/200 mg
Study: 11069312
Drug: Budesonide in
Normalized name: budesonide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide in long-term treatment for corticosteroid-related adverse effects
Study: 8261475
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin following tissue plasminogen activator (t-PA) administration
Study: 8261475
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy with t-PA
Study: 25172877
Drug: Automated insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated insulin pump system
Study: 25172877
Drug: Automated insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated insulin pump system in adolescents with suboptimal baseline BG frequency
Study: 23613806
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 grams daily
Study: 23613806
Drug: Ceftriaxone 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 4 grams daily divided BID
Study: 21043366
Drug: SCE-B 0.3-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCE-B 0.3-mg tablets
Study: 21043366
Drug: SCE-B 1.25-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCE-B 1.25-mg tablets
Study: 14687523
Drug: Bing Shi
Normalized name: Shi Liu Fruit
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bing Shi Yu Shang ointment
Study: 30696573
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (500 mg daily from enrolment prepregnancy until 20 weeks' gestation)
Study: 30696573
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg daily from enrolment prepregnancy until 20 weeks' gestation)
Study: 27022822
Drug: Continued thienopyridine
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued thienopyridine plus aspirin (18 months)
Study: 27022822
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus aspirin (18 months)
Study: 25141111
Drug: Sham blockade
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham blockade (saline injection)
Study: 22607852
Drug: Treatment decisions
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment decisions guided by central BP estimated using radial tonometry
Study: 19411100
Drug: Oral rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral rivaroxaban 10 mg once daily
Study: 19411100
Drug: Subcutaneous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous enoxaparin 30 mg every 12 h
Study: 17548111
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (three 15‐min massages each day for 5 consecutive days)
Study: 12473805
Drug: Valaciclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valaciclovir 500 mg twice daily for 3 days
Study: 10075224
Drug: Medical abortion
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical abortion (600 mg of mifepristone followed by 400 microg of misoprostol after 48 h)
Study: 7926971
Drug: G-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (5 micrograms/kg subcutaneously)
Study: 7926971
Drug: GM-CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (10 micrograms/kg in a 6-h IV infusion)
Study: 2508502
Drug: Metrifonate (MT,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (MT, 10 mg/kg)
Study: 2508502
Drug: Praziquantel (PR,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (PR, 40 mg/kg)
Study: 1103207
Drug: Methylphenidate (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.3 mg/kg)
Study: 29389471
Drug: Abdominal massage
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal massage (15-min, twice a day for three days)
Study: 26398685
Drug: 175 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 175 μg of intravitreal ocriplasmin injection
Study: 19948945
Drug: Diphenhydramine (CYP2D6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (CYP2D6 inhibitor)
Study: 9326185
Drug: Patients informed
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients informed about the real nature of the cap of the pill bottle
Study: 9326185
Drug: Patients not
Normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not informed about the real nature of the cap of the pill bottle
Study: 8330924
Drug: Tinospora cordifolia
Normalized name: tinospora cordifolia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinospora cordifolia (16 mg/kg/day orally)
Study: 8330924
Drug: Conventional management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional management (vitamin K, antibiotics, biliary drainage)
Study: 31525422
Drug: Electrospun nanoscale
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrospun nanoscale P(LLA-CL)/fibrinogen patch
Study: 18235122
Drug: High-dose imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose imatinib (400 mg twice daily)
Study: 17092520
Drug: Arundic acid
Normalized name: Arundic acid
DrugBank: Arundic acid (DB05343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arundic acid (AA) daily infusion for 7 days
Study: 17092520
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily infusion for 7 days
Study: 1844105
Drug: Cefotiam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotiam (2 g with anesthetic induction)
Study: 1844105
Drug: Cefazolin (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (continued administration for 48 hours)
Study: 31628428
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg once daily continuously
Study: 21690317
Drug: Nicotine transdermal
Normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine transdermal patch (open-label trial)
Study: 21690317
Drug: Nicotine transdermal
Normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine transdermal patch (placebo-controlled trial)
Study: 19007589
Drug: Tolvaptan 30
Normalized name: tolvaptan 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 30 mg
Study: 22120091
Drug: Tolvaptan 45
Normalized name: tolvaptan 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 45 mg
Study: 19007589
Drug: Tolvaptan 60
Normalized name: tolvaptan 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 60 mg
Study: 11078176
Drug: Random spot
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random spot urinary albumin creatinine ratio (ACR) >30 mg/g
Study: 1458788
Drug: 3 intravenous
Normalized name: Ammonia N 13 Intravenous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 intravenous pulses of 1000 mg methylprednisolone (MP)
Study: 19692802
Drug: No corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No corticosteroid treatment (control group)
Study: 6148470
Drug: Acyclovir 10
Normalized name: acyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 10 mg/kg 8-hourly for 10 days
Study: 3912977
Drug: Vidarabine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vidarabine 15 mg/kg daily for 10 days
Study: 18434457
Drug: Intravenous meperidine/diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous meperidine/diazepam
Study: 3839991
Drug: Intravenous papaveretum
Normalized name: papaveretum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous papaveretum peroperatively
Study: 28445632
Drug: Olanzapine plus
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine plus sertraline
Study: 12867218
Drug: PO haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO haloperidol (5-20 mg/d)
Study: 12867218
Drug: PO olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO olanzapine (5-20 mg/d)
Study: 2644534
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment (two-week hospitalization with continuous insulin infusion by external artificial pancreas)
Study: 2644534
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (NPH insulin, 1 U per kg body weight per day, in two divided doses)
Study: 30926576
Drug: PMERT (postmastectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMERT (postmastectomy highly conformal electron radiation therapy with bolus)
Study: 30926576
Drug: PMPhRT (postmastectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMPhRT (postmastectomy highly conformal photon radiation therapy without bolus)
Study: 23826890
Drug: Herbal preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal preparation of myrrh, chamomile extract, and coffee charcoal
Study: 20499304
Drug: Sapylin combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapylin combined with chemotherapy
Study: 12756159
Drug: Combined preoperative
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined preoperative and intraoperative methylprednisolone (30 mg/kg 4 hours before bypass and in bypass prime)
Study: 11205676
Drug: Phantom for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phantom for assessing dose in the junction region
Study: 6601256
Drug: Sulfisoxazole therapy
Normalized name: Sulfisoxazole
DrugBank: Sulfisoxazole (DB00263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfisoxazole therapy
Study: 31903697
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 units/mL
Study: 29431598
Drug: M. charantia
Approvals — FDA: no, EMA: no, PMDA: no
Description: M. charantia (2000 mg/day)
Study: 26515411
Drug: Re-irradiation treatment
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-irradiation treatment with a single 8 Gy dose for the worst group identified.
Study: 25325203
Drug: Single-dose regimen:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose regimen: 1 ciprofloxacin 500 mg tablet and 2 metronidazole 250 mg tablets taken 2 hours before biopsy
Study: 25325203
Drug: Multiple-dose regimen:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose regimen: ciprofloxacin and metronidazole every 12 hours from 3 days before biopsy
Study: 25325203
Drug: Single-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose regimen
Study: 25325203
Drug: Multiple-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose regimen
Study: 22691922
Drug: Corn-soya blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn-soya blend (CSB) 71 g daily for 12 weeks
Study: 25524969
Drug: No supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplement (control)
Study: 1873936
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (0.7 +/- 0.1 g/kg/day)
Study: 1465059
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein diet (1.1 +/- 0.3 g/kg/day)
Study: 26809842
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg day-1
Study: 19906761
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² plus Capecitabine 950 mg/m² (DC)
Study: 7588500
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of breath hydrogen excretion between occasional and regular consumption of FOS
Study: 7043728
Drug: Naproxen 750
Normalized name: naproxen 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 750 mg daily
Study: 344088
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 1500 mg daily
Study: 23702498
Drug: Ultrasound guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided platelets rich plasma (PRP) injection and conservative treatment
Study: 23702498
Drug: Conventional conservative
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional conservative treatment only
Study: 11755415
Drug: Vaccines
Normalized name: VACCINES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccines
Study: 12704002
Drug: Taxotere single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxotere single agent (75 mg/m2 iv 1 hour)
Study: 12704002
Drug: Taxotere (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxotere (60 mg/m2 iv 1 hour) plus Adriamycin (50 mg/m2 iv 1 hour)
Study: 10492632
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg of Megestrol Acetate (MA) daily for 12 weeks
Study: 1759762
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ampicillin before insertion of the chest tube
Study: 1759762
Drug: Additional antibiotic
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional antibiotic prophylaxis for as long as the drain was in place
Study: 28634219
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with low-dose nitroglycerin
Study: 26648084
Drug: Intravenous tabalumab
Normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tabalumab (0.01, 0.04, 0.125, 0.5, 2.0, and 8.0 mg/kg for RA; 0.125 or 2.0 mg/kg for SLE)
Study: 26648084
Drug: Subcutaneous tabalumab
Normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous tabalumab (20 mg)
Study: 15459210
Drug: Comparator (vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (vinorelbine 30 mg/m² weekly or mitomycin C 10 mg/m² day 1 and every 28 days plus vinblastine 5 mg/m² day 1, day 14, day 28, and day 42)
Study: 11448376
Drug: Sertraline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (100 mg/d) + Clonazepam (0.5 mg, 3 times daily for 4 weeks)
Study: 11448376
Drug: Sertraline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (100 mg/d) + Placebo Clonazepam
Study: 343788
Drug: Tramadol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (100 mg)
Study: 1096595
Drug: Fluoride-vitamin supplement
Normalized name: ascorbic acid / cholecalciferol / sodium fluoride / vitamin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride-vitamin supplement from infancy
Study: 1096595
Drug: Fluoride-vitamin supplement
Normalized name: ascorbic acid / cholecalciferol / sodium fluoride / vitamin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride-vitamin supplement from age 4
Study: 29788253
Drug: e‐Exercise (3-month
Approvals — FDA: no, EMA: no, PMDA: no
Description: e‐Exercise (3-month intervention with about 5 face-to-face physical therapy sessions integrated with an online application)
Study: 29788253
Drug: Usual physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual physical therapy (conducted according to Dutch physical therapy guidelines)
Study: 29788253
Drug: e‐Exercise and
Approvals — FDA: no, EMA: no, PMDA: no
Description: e‐Exercise and Usual physical therapy
Study: 15452804
Drug: No steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No steroid treatment (NST)
Study: 11420164
Drug: Preoperative intra-aortic
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative intra-aortic balloon counterpulsation therapy (IABP)
Study: 10099058
Drug: Montelukast 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 200 mg once daily
Study: 9679847
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg twice daily
Study: 9516894
Drug: Montelukast 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 50 mg twice daily
Study: 11724223
Drug: Tramadol/APAP (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol/APAP (75 mg/650 mg)
Study: 30052579
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Pc-aCO2 >17 mm Hg with positive ΔPcCO2
Study: 29141365
Drug: Short-acting combined
Normalized name: Short-acting sulfonamide combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting combined oral contraceptives
Study: 16783667
Drug: Bupivacaine (B)
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine (B) + 10 mg Fentanyl (F)
Study: 16783667
Drug: Bupivacaine (B)
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine (B) + 20 mg Fentanyl (F)
Study: 11305405
Drug: Gabapentin at
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin at 24 to 70 mg/kg/day
Study: 8517902
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no heparin)
Study: 21494892
Drug: Tapentadol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol IR 50 mg
Study: 14699540
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid for 5 days postoperatively
Study: 17425493
Drug: Transfusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion therapy
Study: 22692171
Drug: Moxifloxacin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin and meropenem (1 g every 8 hours of meropenem and 400 mg every 24 hours of moxifloxacin)
Study: 22692171
Drug: Moxifloxacin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin and meropenem (combination therapy)
Study: 22692171
Drug: Meropenem alone
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem alone (monotherapy)
Study: 20808013
Drug: Continuous infiltration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infiltration of bupivacaine to the subcutaneous tissue and intra‐articular space for 48 hours, in addition to PCA
Study: 20808013
Drug: Intra‐articular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra‐articular injection of local anaesthetic followed by continuous infiltration of bupivacaine to the subcutaneous tissue and intra‐articular space for 48 hours, in addition to PCA
Study: 20808013
Drug: Patient‐controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient‐controlled analgesia (PCA) with intravenous morphine for 48 hours
Study: 15063406
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (no therapy)
Study: 11140921
Drug: Fluvoxamine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (up to 300 mg daily)